Prevalence and Antibiotic Resistance in Campylobacter spp. Isolated from Humans and Food-Producing Animals in West Africa: A Systematic Review and Meta-Analysis.
Ellis Kobina PaintsilLinda Aurelia OforiSarah AdobeaCharity Wiafe AkentenRichard Odame PhillipsOumou Maiga-AscofareMaike LamshöftJürgen MayKwasi Obiri DansoRalf KrumkampDenise DekkerPublished in: Pathogens (Basel, Switzerland) (2022)
Campylobacter species are one of the leading causes of gastroenteritis in humans. This review reports on the prevalence and antibiotic resistance data of Campylobacter spp. isolated from humans and food-producing animals in West Africa. A systematic search was carried out in five databases for original articles published between January 2000 and July 2021. Among 791 studies found, 38 original articles from seven (41%) out of the 17 countries in West Africa met the inclusion criteria. For studies conducted in food-producing animals, the overall pooled prevalence of Campylobacter spp. was 34% (95% CI: 25-45). The MDR prevalence was 59% (95% CI: 29-84) and half (50%, 13/26) of the animal studies had samples collected from the market. The human studies recorded a lower pooled prevalence of Campylobacter spp. (10%, 95% CI: 6-17), but a considerably higher rate of MDR prevalence (91%; 95% CI: 67-98). The majority (85%, 11/13) of the human studies took place in a hospital. Campylobacter jejuni and Campylobacter coli were the most common species isolated from both animals and humans. Our findings suggest that Campylobacter spp. is highly prevalent in West Africa. Therefore, improved farm hygiene and 'One Health' surveillance systems are needed to reduce transmission.
Keyphrases
- biofilm formation
- risk factors
- antimicrobial resistance
- case control
- public health
- endothelial cells
- healthcare
- escherichia coli
- randomized controlled trial
- multidrug resistant
- pseudomonas aeruginosa
- clinical trial
- staphylococcus aureus
- machine learning
- human health
- emergency department
- systematic review
- big data
- mental health
- risk assessment
- induced pluripotent stem cells
- electronic health record
- study protocol